Check up: here’s what’s happening with 140 ASX small cap health stocks
Health & Biotech
Health & Biotech
Link copied to
Here’s our monthly wrap of all the news driving ASX health stocks
Small cap health stocks have taken investors on a thrilling ride over the past month or two.
HIV fighter Biotron (ASX:BIT) hit 20-bagger status — soaring 2000 per cent on the back of positive trial results.
Bard1 (ASX:BD1) shares shot up 450 per cent after it said it was adapting an ovarian cancer test to breast cancer.
Suda Pharma (ASX:SUD) jumped 150 per cent after striking a deal with an Indian company to develop its migraine drug in the US.
Semen separator Memphasys (ASX:MEM) and muscular dystrophy researcher Antisense Therapeutics (ASX:ANP) both jumped 300 per cent — attracting ASX queries along the way.
Despite these break-outs, more than half of health stocks have lost ground over the past month.
Of the ASX’s 140-odd small cap health stocks, 78 saw their share prices fall, 53 improved and 11 were flat.
>> Scroll down for a table showing the performance of small cap health stocks over the past month
Memphasys (ASX:MEM) was the best-performing health stock of the past month — up 153 per cent to 3.8c — despite a lack of news.
Memphasys is developing a membrane codenamed Felix that separates quick swimmers from flabby floaters to improve IVF procedures.
Memphasys says it’s “entered a pivotal stage in the commercial development” of Felix, signing “the first of a number of leading international andrology and IVF clinics as partners to conduct invitro [or test tube] assessments”.
Memphasys is hoping for European regulatory approval in late 2019 which would allow for human trials.
Bard1 Life Sciences (ASX:BD1) also enjoyed a good month, up 150pc after adding breast cancer to its clinical lineup.
BARD1 has combined a biomarker and an algorithm into a blood test that can detect 6 per cent more cases of ovarian cancer than simply by using the algorithm.
It is now adapting that test to breast cancer. A lung cancer test is further back in the development process.
Both Suda Pharmaceuticals (ASX:SUD) and Proteomics International (ASX:PIQ) are in the top 10 best-performing small cap health stocks over the past month thanks to recent news.
Proteomics says the first commercial batches of its test for predicting the onset of diabetic kidney disease will be shipped later this month.
Paradigm Biopharma (ASX:PAR) is also up on very recent news, reporting earlier this week that its treatment for osteoarthritis patients was having a significant impact on knee pain.
Its shares are up 36 per cent in the past month, and up 199pc year-on-year.
Suda struck struck a deal with an Indian pharma company to develop its migraine drug in the US, while Proteomics said the first commercial batches of its test for predicting the onset of diabetic kidney disease will be shipped later this month.
Despite hitting 20-bagger status in October biotech darling Biotron (ASX:BIT) has lost half its recent gains and does not feature as a positive mover over the past month.
It’s till up 1000 per cent since September though.
At the other end of the scale, ResApp (ASX:RAP) shares have drifted 52 per cent in the past month, after investors questioned the results of its US coughing app re-trial.
For what it’s worth, ResApp boss Tony Keating told Stockhead done a better job of educating the market in what a good result looked like that his company could have , saying that the company was ready for its next stage of growth.
Here’s a table showing price performance for the ASX’s small cap health stocks over the past month.
Swipe or scroll to reveal full table. Click headings to sort